Previous reports showed that, in contrast with insulin therapy alone, adding SGLT-2 inhibitors significantly reduced HbA1c, insulin dose, and body weight in T1DM (15, 16). The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.